ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ) has a MoatMap StockRank of 30/100 based on Quality (46/100), Value (35/100), and Momentum (37/100) factor scores. The current signal is SELL. ApicHope is a domestic Chinese pharmaceutical company focused on pediatric and generic drugs. It lacks the global scale, regulatory moats, and high-utilization CDMO characteristics required to benefit from our CDMO pricing power theme.
ApicHope Pharmaceutical Group Co., Ltd. develops, manufactures, and markets specialty pharmaceuticals, with a core focus on pediatric medicines, generic drugs, and active pharmaceutical ingredients (APIs). The company is a market leader in China's pediatric healthcare segment, leveraging a comprehensive portfolio of child-friendly formulations. It is characterized by its robust R&D pipeline and strong brand recognition among domestic hospitals and pharmacies.
| Price | $5.05 |
| Market Cap | $2.9B |
| P/E (TTM) | 85.77 |
| P/E (Forward) | 57.18 |
| Price/Book | 8.74 |
| Return on Equity | 9.7% |
| Return on Invested Capital | -10.7% |
| Debt/Equity | 105.73 |
| Gross Margin | 57.4% |
| Operating Margin | 6.1% |
| Revenue Growth | 2.3% |
| Free Cash Flow | $9M |
ApicHope Pharmaceutical Group Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).